BioMarin Pharmaceutical Inc. (BMRN) FinancialsBMRNBioMarin Pharmaceutical Inc.

BioMarin Pharmaceutical Inc. (BMRN) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is POMBILITI OPFOLDA, accounting for 103.1% of total sales, equivalent to $1.02B. Other significant revenue streams include Voxzogo and Vimizim. Understanding this composition is critical for investors evaluating how BMRN navigates market cycles within the Pharmaceuticals industry.

Evaluating the bottom line, BioMarin Pharmaceutical Inc. maintains a gross margin of 72.08%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at 16.91%, while the net margin is 4.52%. These profitability ratios, combined with a Return on Equity (ROE) of 1.18%, provide a clear picture of how effectively BMRN converts its operational activities into shareholder value.

In the context of the broader market, BMRN competes directly with industry leaders such as ELAN and ARWR. With a market capitalization of $13.04B, it holds a leading position in the sector. When comparing efficiency, BMRN's gross margin of 72.08% stands against ELAN's 48.17% and ARWR's 100.00%. Such benchmarking helps identify whether BioMarin Pharmaceutical Inc. is trading at a premium or discount relative to its financial performance.

BioMarin has shown solid financial performance with a gross margin of 72.08% in Q2 2026 and a net income of $44.76 million for the same quarter, reflecting ongoing profitability despite recent challenges.